Bucladesine sodium is a derivative of cyclic-AMP with cardiac stimulant and
peripheral vasodilatory properties. It is reported to be useful in cardiac
insufficiency, especially after heart surgery.
Daiichi Seiyaku; Seishin Seiyaku (Japan)
Bucladesine sodium is an analog of cyclic AMP that stimulates cAMP-dependent protein kinase. It has vasodilator properties and is used as a cardiac stimulant.
ChEBI: Bucladesine sodium is a 3',5'-cyclic purine nucleotide.
N6,2′-O-Dibutyryladenosine 3′,5′-cyclic monophosphate sodium salt has been used:
as a medium supplement for neural crest stem cells (NCSCs) differentiation
as a component of thawing medium for cryopreserved human iPSC (induced pluripotent stem cell)-derived neurons
in serum-free Dulbecco′s modified eagle′s medium (DMEM) to induce astrocyte differentiation
A cell-permeable cAMP analog that preferentially activates cAMP-dependent protein kinase (PKA). Causes an increase in the steady state level of parathyroid hormone-related peptide mRNA. Also acts as a Hh pathway antagonist. Shown to induce apoptosis in vascular smooth muscle cells.
Cell-permeable cAMP analog that activates cAMP dependent protein kinase (PKA).
1) Bartsch?et al.?(2003),?Bioactivatable, membrane-permeant analogs of cyclic nucleotides as biological tools for growth control of C6 glioma cells; Biol. Chem.,?384?1321
2) Carranza?et al.?(1998),?Protein kinase A induces recruitment of active Na+,K+-ATPase units to the plasma membrane of rat proximal convoluted tubule cells; J. Physiol.,?15?511
3) Hei?et al.?(1991),?Lack of correlation between activation of cyclic AMP-dependent protein kinase and inhibition of contraction of rat vas deferens by cyclic AMP analogs; Mol. Pharmacol.,?39?233
4) Imamura?et al.?(1998),?Differential expression of dystrophin isoforms and utrophin during dibutyryl-cAMP-induced morphological differentiation of rat brain astrocytes; Proc. Natl. Acad. Sci. USA,?95?6139
5) Xia?et al.?(2016),?Transcriptional comparison of human induced and primary midbrain dopaminergic neurons; Sci. Rep.,?6?20270
